81 Scientists have identified a key group of genetic alterations, known as oncohistones, that are reshaping how researchers understand the development of bone cancer. These mutations, found in the proteins that package DNA, are offering new clues about the root causes of certain bone tumours and may pave the way for targeted therapies. The findings were published in the journal Cell Death and Differentiation. Unlike traditional genetic mutations that affect genes themselves, oncohistones disrupt the regulation of gene activity by altering the proteins (histones) that help organise and control access to DNA. The discovery of these mutations in aggressive paediatric brain cancers several years ago triggered interest in whether similar changes might be driving other forms of cancer. Now, new research is highlighting the importance of these histone mutations in bone tumours, particularly in two rare but debilitating types: chondroblastoma and giant cell tumour of bone. Both tumours primarily affect young people and tend to grow in the epiphysis, or end parts, of long bones. While classified as benign, they can behave aggressively and occasionally transform into malignant disease. Strikingly, nearly all cases of these tumours contain single-point mutations in a specific histone variant, H3.3. These mutations are believed to interfere with the normal processes of cell differentiation and may also influence how tumour cells interact with their surrounding environment. In chondroblastoma, the H3.3-K36M mutation inhibits enzymes responsible for maintaining proper methylation of histones. This disruption affects how genes are turned on and off, leading to abnormal cell growth. Researchers have shown in laboratory models that this mutation alone is enough to drive the development of tumours resembling chondroblastoma, highlighting its direct role in cancer formation. Giant cell tumour of bone, on the other hand, is most often associated with a different mutation in H3.3: the G34W variant. This mutation has a more complex mechanism, influencing not only gene regulation but also the tumour’s surrounding microenvironment. Mutant cells appear to secrete abnormal levels of factors like RANKL, which stimulate the formation of large, multinucleated osteoclast-like cells. This altered cell signalling may help the tumour grow and resist treatment. Recent evidence also shows that these mutations interfere with normal cell differentiation, locking cells in a progenitor state and preventing them from maturing. This has implications for the tumour’s behaviour and response to therapy. Scientists are now investigating whether these insights could lead to new treatment strategies, including drugs that restore normal epigenetic regulation. Although much of the early research on oncohistones has focused on brain tumours, the parallels seen in bone cancers suggest that these mutations may have a wider role in oncology than previously thought. Researchers caution, however, that much remains to be understood, especially around how these mutations influence the tumour microenvironment and immune response. The hope is that, by targeting these epigenetic changes, future therapies may be able to not only halt tumour growth but also reverse some of the cellular changes that drive these rare and difficult-to-treat cancers.